Lars Dyrskjøt, Professor at Aarhus University, shared on LinkedIn about a recent article he and his colleagues co-authored, adding:
“ctDNA-guided postoperative management in muscle-invasive bladder cancer
We have just published the results of the TOMBOLA trial in Annals of Oncology, evaluating tumor-informed circulating tumor DNA (ctDNA) as a tool to guide postoperative management after radical cystectomy.
In this national, multicenter study, we show that ctDNA-guided strategies can support both treatment escalation and de-escalation across low- and high-risk patients:
- ctDNA identifies patients at high risk of relapse who would not qualify for adjuvant immunotherapy under current guideline criteria
- ctDNA-negative patients — including those with high risk pathological features — have excellent outcomes without adjuvant treatment
- Early immunotherapy initiated at molecular relapse is associated with high response rates at very low disease burden
These findings extend recent randomized evidence by demonstrating how ctDNA-guided approaches can be applied across broader risk groups and integrated into routine postoperative care.
A sincere thank you to all patients who participated in the study, and to my co-authors and collaborators across the Danish centers for an outstanding team effort.”
Title: ctDNA-Guided Immunotherapy following Radical Cystectomy for Muscle-Invasive Bladder Cancer: Results from the TOMBOLA Trial
Authors: L. Dyrskjøt, K. Birkenkamp-Demtröder, I. Nordentoft, T. Strandgaard, S.V. Lindskrog, R.V. Milling, S.K. Körner, S.B. Brandt, M. Knudsen, T.G. Andreasen, C.F. Hansen, P. Lamy, G. Lam, L.H. Dohn, K. Fabrin, A. Carus, A.C. Petersen, U.N. Joensen, H. Pappot, P.S. Holt, N.V. Jensen, M. Agerbæk, J.B. Jensen
Read the Full Article on Annals of Oncology:
More posts featuring Lars Dyrskjøt.
